ClinicalTrials.gg
CompletedNCT05395754Updated Dec 5, 2024

Assessing the Feasibility and Preliminary Impact of a mHealth App on Reducing STI Risk in Black MSM PrEP Users

An interventional study of App Intervention in STI, Sexually Transmitted Diseases and Pre-exposure Prophylaxis, sponsored by Louisiana State University Health Sciences Center in New Orleans. Completed at 2 sites in United States. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-05.

Sponsored by Louisiana State University Health Sciences Center in New Orleans · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Male
01

Study summary

The study will recruit 120 Black men who have sex with men (BMSM) from the local area, New Orleans. The main purpose of this research study is to test the effect of a new smartphone application, "PCheck," on reducing the incidence of STIs, compared to routine care through the LSU-Crescent Care Sexual Health/PrEP Clinic.

Read the detailed description

This unblinded, randomized study will determine the feasibility and preliminary impact of our adapted PCheck app in reducing STI infections in Black MSM PrEP users. Over 24 months, the research staff will prospectively enroll BMSM entering or already engaged in PrEP care. Participants will be randomly allocated 2:1 to the PCheck intervention versus standard of care using an automated system for randomization; the rationale for heavier allocation to the intervention is to allow for more participants to interact on the app (colleagues at the University of Virginia who have tested a similar app advised that a "critical mass" of roughly 20 participants using the community forum is needed for discussions to begin organically). Randomization will occur upon first meeting with the clinical research coordinator (CRC).

At enrollment, those randomized to the intervention arm will receive hands-on app onboarding training by the CRC. The training is anticipated to take 15-30 minutes and will include an overview of the app's features and how to use each, coaching about using the daily check-in feature to record mood, stress levels, and recent sexual activity and condom use, guidance on creating an anonymous introductory post to the community board, and practice using each of the PCheck features. Participants allocated to the intervention arm will receive the intervention (use of the PCheck app) for 24 months of follow-up. Participants will be encouraged to use the app as much as they wish throughout the study and will be informed that there will be no set expectation for how frequently they must use the app, although they will be encouraged to use it regularly to "thoroughly test it". The app will send notification reminders to "check in" (in other words, use the daily check-in feature to track their mood, stress, and behaviors related to STI-prevention over time). The notification settings can be adjusted in phone settings by the participant.

For participants receiving the app intervention, study staff will also schedule a follow-up call within two weeks after enrollment to encourage engagement, to talk through any difficulties that arise with using the app and to troubleshoot. During the 24 months of enrollment, study staff will contact participants at the 1, 2, 4, and 12 week marks after they stop showing usage on the app to encourage re-engagement and address any technical or other barriers.

To encourage engagement with the app, the research team will post short quizzes on the app's landing page and reminders about them on the community message board. The study will pilot once-a-day trivia questions, and adjust the frequency of trivia postings pending on participant engagement and/or feedback. Each set of trivia questions will take a couple minutes to complete and will ask 1-2 questions such as general knowledge about STIs, sexual health and wellness, and/or general New Orleans-specific or LGBTQI+ history. All participants who complete four of the quizzes for the week will be entered into a raffle for an additional $10 loaded onto their Clincard.

For app users, data will be extracted directly from the PCheck app, including app usage and data from the app's check-in, PrEP adherence, and STI prevention features. App data will be de-identified except for anonymous username and study ID number, which can be linked to identifying information in order to contact individuals not showing usage on the app, as described above.

For all participants, STI (syphilis, gonorrhea, chlamydia, HIV) screening will occur every three months and HCV screening every 6-12 months over 24 months of follow-up as part of routine care. Every three months, all participants will also complete self-administered questionnaires with demographic, social, and behavioral assessments. Participants allocated to the standard of care control group will be informed that their participation entails attending routine PrEP appointments, including STI screening, and completing the quarterly surveys. For those in the intervention arm, participants will also answer questions aimed at assessing app acceptability, feasibility, and usability.

02

Conditions studied

  • STI
  • Sexually Transmitted Diseases
  • Pre-exposure Prophylaxis

Keywords

  • BMSM
  • STI
  • Sexually Transmitted Infection
  • Mobile health
  • PrEP
  • pre-exposure prophylaxis
  • MSM
03

In context

Sexually Transmitted Diseases

435 studies on the registry are indexed under Sexually Transmitted Diseases; 73 are open to participants now.

This study's enrollment of 71 is below the median of 460 across 356 interventional studies indexed under Sexually Transmitted Diseases.

Browse Sexually Transmitted Diseases studies →

Lead sponsor

Louisiana State University Health Sciences Center in New Orleans is the lead sponsor of 72 studies on the registry; 12 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cisgender man who has sex with cisgender men (MSM) including gay, bisexual, or other MSM
  • Age 18-35 years
  • Black race or multi-racial including Black race
  • Prescribed, administered or otherwise taking PrEP via routine care or PrEP clinical trial
  • Smartphone possession

Exclusion criteria

Exclusion criteria:

  • Unable to read and write
  • Not fluent in English
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    PCheck

    Participants allocated to the intervention arm will receive the intervention (use of the PCheck app) for 12 months of follow-up. Participants will be encouraged to use the app as much as they wish throughout the study and will be informed that there will be no set expectation for how frequently they must use the app, although they will be encouraged to use it regularly to "thoroughly test it". The app will send notification reminders to "check in" (in other words, use the daily check-in feature to track their mood, stress, and behaviors related to STI-prevention over time). The notification settings can be adjusted in phone settings by the participant. To encourage peer support and a sense of community, users can interact with community members anonymously through a message board, monitored by research staff. Participants in the intervention will continue routine PrEP care and STI testing through the clinic.

    Device: App Intervention

  • No intervention
    Routine Care

    Participants in the routine care arm will continue routine PrEP care and STI testing through the clinic.

Interventions

  • DeviceApp Intervention

    Use of the PCheck app, an app encouraging STI prevention behaviors.

06

What researchers measure

Primary outcomes

  1. STI incidence

    New diagnosis of syphilis, gonorrhea, chlamydia, or hepatitis C per 100 person-years. Number of new HIV diagnoses.

    Time frame: 24 months

Secondary outcomes

  1. Social Support

    Scaled score on the Social Provisions Scale-10. The minimum score is 10 and maximum score is 40. Higher scores indicate a higher degree of social support.

    Time frame: 24 months

  2. Social Isolation

    Scaled score on the Patient-Reported Outcomes Measurement Information System (PROMIS) Social Isolation Subscale. Higher scores indicate a higher degree of social isolation or disconnection from others. The minimum score is 4 and maximum score is 20.

    Time frame: 24 months

07

Study locations

2 sites
  • CrescentCare PrEP Clinic
    New Orleans, Louisiana 70119, United States
  • LSU-CrescentCare Sexual Health Center
    New Orleans, Louisiana 70119, United States
08

References and documents

Study documents

  • Informed consent form · Nov 20, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Aug 2024, 26 months.

Of 149 non-industry interventional studies with no phase under Sexually Transmitted Diseases, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's 26 months is below that.

Counting every sponsor, half of 159 studies reached it within 29 months; a quarter within 15 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2022
First posted
May 27, 2022
StartActual
Jun 1, 2022
Primary completionActual
Aug 31, 2024
CompletionActual
Aug 31, 2024
Last update
Dec 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05395754
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Responsible party
Meredith Clement (Assistant Professor, Louisiana State University Health Sciences Center in New Orleans) — Principal investigator
First posted
May 27, 2022
Start date
Jun 1, 2022
Primary completion
Aug 31, 2024
Completion
Aug 31, 2024
Last update
Dec 5, 2024

Study contacts

Meredith Clement, MD
principal investigator · LSUHSC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion